Cyclooxygenase-2 gene -1195G/A genotype is associated with the risk of HBV-induced HCC: A case-control study in Han Chinese people

Frontiers of Medicine in China

Volumn 4, Issue 1, 2010, Pages 90-95

  Liu, Li Feng ^a   Zhang, Jin Liang ^a   Chen, Qiong ^a   Chang, Ying ^a   Lin, Ju Sheng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cyclooxygenase 2 gene; Hepatitis B virus infection; Primary hepatocellular carcinoma; Single nucleotide polymorphisms; Susceptibility

Indexed keywords

EID: 76649110187     PISSN: 16737342     EISSN: 16737458     Source Type: Journal    
DOI: 10.1007/s11684-010-0021-x     Document Type: Article

References (48)

1. Needleman P, Turk J, Jakschik B A, Morrison A R, Lefkowith J B. Arachidonic acid metabolism. Annu Rev Biochem, 1986, 55: 69-102.
2. Williams C S, Mann M, DuBois R N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 1999, 18: 7908-7916.
3. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasias. Ann Clin Lab Sci, 2000, 30: 3-21.
4. Trifan O C, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. Cell Mol Med, 2003, 7(3): 207-222.
5. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev, 2000, 19(1-2): 19-27.
6. Vane J R, Bakhle Y S, Botting R M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol, 1998, 38: 97-120.
7. SmithWL, Garavito RM, DeWitt D L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem, 1996, 271(52): 33157-33160.
8. Taketo M M. COX-2 and colon cancer. Inflamm Res, 1998, 47(Suppl 2): S112-S116.
9. Ding X Z, Tong W G, Adrian T E. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res, 2000, 20(4): 2625-2631.
10. Li M, Wu X, Xu X C. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome cdependent pathway. Clin Cancer Res, 2001, 7(4): 1010-1016.
11. Sheng H, Shao J, Washington M K, DuBois R N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem, 2001, 276(21): 18075-18081.
12. Chen W S, Wei S J, Liu JM, Hsiao M, Kou-Lin J, Yang W K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer, 2001, 91(6): 894-899.
13. Masferrer J L, Leahy K M, Koki A T, Zweifel B S, Settle S L, Woerner B M, Edwards D A, Flickinger A G, Moore R J, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 2000, 60(5): 1306-1311.
14. Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107(4): 1183-1188.
15. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res, 1998, 58(22): 4997-5001.
16. Chan G, Boyle J O, Yang E K, Zhang F, Sacks P G, Shah J P, Edelstein D, Soslow R A, Koki A T, Woerner B M, Masferrer J L, Dannenberg A J. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res, 1999, 59(5): 991-994.
17. Ratnasinghe D, Tangrea J, Roth M J, Dawsey S, Hu N, Anver M, Wang Q H, Taylor P R. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey. Anticancer Res, 1999, 19(1A): 171-174.
18. Fujita H, Koshida K, Keller E T, Takahashi Y, Yoshimito T, Namiki M, Mizokami A. Cyclooxygenase-2 promotes prostate cancer progression. Prostrate, 2002, 53(3): 232-240.
19. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett, 2003, 191(2): 125-135.
20. Gupta S, Srivastava M, Ahmad N, Bostwick D G, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate, 2000, 42(1): 73-78.
21. Chi-Man Tang T, Tung-Ping Poon R, Fan S T. The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma. Biomedicine & Pharmacotherapy, 2005, 59 Suppl 2: S311-S316.
22. Lu W, Dong J, Huang Z, Guo D, Liu Y, Shi S. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroen Hepatol, 2008, 2(12): 1874-1878.
23. Thorgeirsson S S, Grisham J W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet, 2002, 31(4): 339-346.
24. Buendia M A. Genetics of hepatocellular carcinoma. Semin Cancer Biol, 2000, 10(3): 185-200.
25. Cox D G, Pontes C, Guino E. Polymorphisms in prostaglandin synthase 2/cyclooxygen2 (PTGS2/COX-2) and risk of colorectal cancer. Br J Cancer, 2004, 91(2): 339-343.
26. Li M, Wu X, Xu X C. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome cdependent pathway. Clin Cancer Res, 2001, 7(4): 1010-1016.
27. Sheng H, Shao J, Washington M K, DuBois R N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem, 2001, 276(21): 8075-8081.
28. Chen W S, Wei S J, Liu JM, Hsiao M, Kou-Lin J, Yang W K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer, 2001, 91(6): 894-899.
29. Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107(4): 1183-1188.
30. Hu Z, Miao X, Ma H, Wang X, Tan W, Wei Q, Lin D, Shen H. Common polymorphism in the 3' UTR of cyclooxygenase 2 /prostaglandin synthase 2 gene and risk of lung cancerin a Chinese population. Lung Cancer, 2005, 48(1): 11-17.
31. Chan G, Boyle J O, Yang E K, Zhang F, Sacks P G, Shah J P, Edelstein D, Soslow R A, Koki A T, Woerner B M, Masferrer J L, Dannenberg A J. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res, 1999, 59(5): 991-994.
32. Ratnasinghe D, Tangrea J, Roth M J, Dawsey S, Hu N, Anver M, Wang Q H, Taylor P R. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunhistochemical survey. Anticancer Res, 1999, 19(1A): 171-174.
33. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y, Qiang B, Kadlubar F F, Lin D. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology, 2005, 129(2): 565-576.
34. Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, Matsuura N, Wakasa K, Nakamori S, Sakon M, Monden M. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res, 1999, 5(12): 4005-4012.
35. Morinaga S, Yamamoto Y, Noguchi Y, Imada T, Rino Y, Akaike M, Sugimasa Y, Takemiya S, Kameda Y, Takanashi Y. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. J Gastroenterol Hepatol, 2002, 17(10): 1110-1116.
36. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, Kurohiji T, Sata M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 1999, 29(3): 688-696.
37. Casado M, Callejas N A, Rodrigo J, Zhao X, Dey S K, Bosca L, Martin-Sanz P. Contribution of cyclooxygenase 2 to liver regeneration after partial hepatectomy. FASEB J, 2001, 15(11): 2016-2018.
38. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Gastroenterology, 2003, 125(2): 556-571.
39. Reilly T P, Brady J N, Marchick M R, Bourdi M, George J W, Radonovich M F, Pise-Masison C A, Pohl L R. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol, 2001, 14(12): 1620-1628.
40. Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K, Eguchi K. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology, 2002, 35(5): 1117-1124.
41. Kern M A, Schubert D, Sahi D, Schoneweiss MM, Moll I, Haugg A M, Dienes H P, Breuhahn K, Schirmacher P. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology, 2002, 36(4 Pt 1): 885-894.
42. Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, Matsuura N, Wakasa K, Nakamori S, Sakon M, Monden M. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res, 1999, 5(12): 4005-4012.
43. Nunez O, Fernandez-Martinez A, Majano P L, Apolinario A, Gomez-Gonzalo M, Benedicto I, Lopez-Cabrera M, Bosca L, Clemente G, Garcia-Monzon C, Martin-Sanz P. Increased intrahepatic cyclooxygenase-2, matrix metalloproteinase-2, and matrix metalloproteinase-9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut, 2004, 53(11): 1665-1672.
44. Panguluri R C, Long L O, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles R A. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis, 2004, 25(6): 961-966.
45. Gao J, Ke Q, Ma H X, Wang Y, Zhou Y, Hu Z B, Zhai X J, Wang X C, Qing JW, Chen W S, Jin G F, Liu J Y, Tan Y F, Wang X R, Shen H B. Functional polymorphism in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A, 2007, 70(11): 908-915.
46. Tazawa R, Xu X M, Wu K K. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun, 1994, 203(1): 190-199.
47. Liu F, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, Dong C, Shen L, Li J, Deng D, Lin D, You W. Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology, 2006, 130(7): 1975-1984.
48. Vogel U, Christensen J, Wallin H, Friis S, Nexø BA, Tjønneland A. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res, 2007, 617(1, 2): 138-146.